Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06357533
Title	Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)
Acronym	TROPION-Lung10
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-squamous non-small cell carcinoma lung non-small cell carcinoma
Therapies	Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| ITA \| HUN \| GBR \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS